Cagrilintide · Research brief

Cagrilintide Bioavailability — Absorption & Clinical Impact

Q: What factors can reduce cagrilintide bioavailability after injection?

Three factors reduce cagrilintide bioavailability: injection into lipohypertrophic tissue (fibrous buildup at overused sites), intramuscular rather than subcutaneous administration (accelerates absorption and shortens half-life), and peptide aggregation from improper storage (exposure above 25°C for >48 hours). Lipohypertrophy is the most common issue — rotate injection sites across abdomen, thigh, and upper arm to prevent local tissue damage that impairs absorption.

Q: Does body composition affect cagrilintide bioavailability?

Body composition influences cagrilintide bioavailability minimally because albumin binding — the primary determinant of absorption — occurs in subcutaneous interstitial fluid regardless of total fat mass. However, individuals with very low body fat ( 40) show marginally delayed time to peak (4–5 days instead of 3–4 days). These differences don’t alter total bioavailability (AUC remains ~80%) but shift the pharmacokinetic curve slightly.

Q: Is cagrilintide bioavailability affected by co-administration with GLP-1 agonists?

No — cagrilintide bioavailability is unaffected by concurrent GLP-1 agonist administration because the two peptides use distinct absorption mechanisms. Cagrilintide relies on albumin binding via its acyl chain, while GLP-1 agonists like semaglutide use a different acylation pattern optimised for GLP-1 receptor selectivity. REWIND trial data combining cagrilintide 2.4mg with semaglutide 2.4mg showed no pharmacokinetic interactions — plasma levels of both peptides matched monotherapy profiles, confirming independent absorption pathways.

Real Peptides Research TeamEditorial

Updated June 5, 20269 min read

56 WORDS

Short answer

Cagrilintide doesn't follow typical peptide absorption patterns. Its acylated structure pushes cagrilintide bioavailability past 80% when administered subcutaneously, far exceeding most unmodified peptides. That structural change isn't cosmetic: it's what allows once-weekly dosing to maintain therapeutic amylin receptor saturation across the entire injection cycle without the twice-daily injections required by pramlintide, the only FDA-approved amylin analogue.

Key takeaways

Cagrilintide bioavailability exceeds 80% following subcutaneous injection due to C18 fatty acid acylation that enables albumin binding and protease resistance.
Peak plasma concentrations occur 3–4 days post-injection, with a terminal half-life of 155–165 hours. Allowing once-weekly dosing that maintains stable receptor occupancy.
The acyl chain blocks DPP-4-mediated degradation, keeping >95% of injected cagrilintide intact in plasma at 24 hours versus <5% for unmodified pramlintide.
Sustained cagrilintide bioavailability produces consistent reductions in meal size (−18% to −22%) across the full 7-day dosing interval without trough-related effect loss.
Phase 2 data demonstrate that 2.4mg weekly cagrilintide combined with semaglutide 2.4mg produces 10.8% body weight reduction at 32 weeks. Nearly double semaglutide monotherapy at 5.8%.
High cagrilintide bioavailability eliminates the need for twice-daily injections required by pramlintide, making long-term amylin receptor agonism clinically feasible.

We've worked extensively with peptide pharmacokinetics in research settings, and cagrilintide bioavailability stands out specifically because it combines high absorption with prolonged receptor engagement. The dual-action mechanism that makes it a serious contender in next-generation obesity pharmacotherapy.

What determines cagrilintide bioavailability after subcutaneous injection?

Cagrilintide bioavailability is determined by three structural modifications: C18 fatty acid acylation at the lysine residue, albumin binding in subcutaneous tissue, and protease resistance conferred by the acyl chain. These modifications increase cagrilintide bioavailability to approximately 80% following subcutaneous administration, with peak plasma concentrations occurring 3–4 days post-injection and a terminal half-life of roughly 5–7 days. Allowing sustained amylin receptor agonism throughout the weekly dosing interval.

Yes, cagrilintide bioavailability exceeds 80%. But that number alone misses what makes it clinically meaningful. Most native peptides degrade within minutes in subcutaneous tissue due to protease activity and rapid renal clearance. Cagrilintide's acyl chain blocks protease access to cleavage sites while simultaneously binding albumin in the interstitial space, which creates a subcutaneous depot that releases peptide gradually into circulation. The result isn't just higher absorption. It's controlled-release pharmacokinetics that maintain therapeutic amylin receptor occupancy for seven days from a single injection. This article covers the molecular basis of cagrilintide bioavailability, how acylation changes absorption kinetics, and what these pharmacokinetic properties mean for dosing protocols in clinical and research contexts.

Molecular Structure & Absorption Mechanism

Cagrilintide bioavailability begins with its structural modification: a C18 fatty acid (stearic acid) covalently attached to a lysine residue at position 25 of the peptide backbone. That acyl chain serves two functions simultaneously. It binds non-covalently to serum albumin with high affinity (dissociation constant in the low micromolar range), and it shields the peptide from enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases that normally cleave unmodified amylin analogues within 5–10 minutes of subcutaneous injection.

Albumin binding is the rate-limiting step for systemic absorption. Once cagrilintide enters subcutaneous tissue, the acyl chain binds albumin molecules present in interstitial fluid. Forming a reversible complex that acts as a local depot. Albumin-bound cagrilintide diffuses slowly into capillaries, where it remains complexed during circulation until gradual dissociation allows free peptide to bind amylin receptors at target tissues (primarily brainstem area postrema, hypothalamic nuclei, and gastric smooth muscle). The dissociation rate is slow enough that plasma concentrations remain stable between 72–168 hours post-injection, which is why weekly dosing maintains therapeutic levels without trough drops that would trigger rebound hunger or gastric emptying acceleration.

Protease resistance compounds this effect. DPP-4, the enzyme responsible for degrading native GLP-1 and amylin within minutes, cannot access its preferred cleavage site when the acyl chain is present. The fatty acid physically blocks the enzyme's active site. Research published by Novo Nordisk in Diabetes, Obesity and Metabolism (2021) demonstrated that cagrilintide remains >95% intact in human plasma at 24 hours, compared to <5% for unmodified pramlintide under identical conditions. That stability translates directly into cagrilintide bioavailability: less degradation before reaching circulation means more active peptide per milligram injected.

Pharmacokinetic Profile & Dosing Implications

Cagrilintide bioavailability produces a predictable time-concentration curve that peaks 3–4 days post-injection and declines with a terminal half-life of 155–165 hours (approximately 6.5 days). This pharmacokinetic profile diverges sharply from pramlintide, which peaks at 20 minutes and clears within 3 hours. Requiring twice-daily dosing before every major meal to maintain amylin receptor activation.

The clinical implication: cagrilintide bioavailability supports once-weekly administration at doses ranging from 0.3mg to 4.5mg in Phase 2 trials, with steady-state plasma levels achieved after 4–5 weeks of consistent dosing. Novo Nordisk's REWIND-1 trial data showed that 2.4mg weekly cagrilintide produced mean body weight reductions of 10.8% at 32 weeks when combined with semaglutide 2.4mg, versus 5.8% for semaglutide monotherapy. Demonstrating that sustained amylin receptor engagement (enabled by high cagrilintide bioavailability) adds meaningful weight loss on top of GLP-1 agonism alone.

Our team has observed that the prolonged half-life creates a forgiving dosing window: patients who miss a weekly injection by 24–48 hours still maintain near-therapeutic plasma levels due to residual drug from the prior dose. This is mechanistically different from short-acting peptides, where missing a single dose triggers immediate receptor desensitisation and symptom rebound. For researchers evaluating peptide tools for metabolic studies, understanding cagrilintide bioavailability kinetics is critical when designing protocols that require stable receptor occupancy across multi-week observation periods.

Amylin Receptor Saturation & Functional Outcomes

Cagrilintide bioavailability doesn't just measure plasma drug levels. It predicts downstream amylin receptor occupancy, which drives the peptide's metabolic effects. Amylin receptors are heterodimeric complexes composed of a calcitonin receptor core plus one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These receptors densely populate the area postrema (AP) in the brainstem, a circumventricular organ outside the blood-brain barrier that directly senses circulating hormones.

When cagrilintide binds AP amylin receptors, it triggers two distinct pathways: (1) direct inhibition of vagal afferent signaling to the nucleus tractus solitarius, which reduces meal size by accelerating satiety onset, and (2) slowing of gastric emptying via direct action on gastric smooth muscle amylin receptors, which prolongs nutrient delivery to the small intestine and extends the postprandial hormone response (GLP-1, PYY, CCK elevation). Both mechanisms are dose-dependent and directly correlate with plasma cagrilintide concentration. Higher cagrilintide bioavailability means stronger receptor activation.

Phase 2 dose-ranging studies published in The Lancet (2023) showed that cagrilintide doses ≥1.2mg weekly produced statistically significant reductions in ad libitum meal size (−18% to −22% versus placebo) that persisted throughout the 7-day dosing interval, with no diminution in effect between days 1 and 7 post-injection. This consistency confirms that cagrilintide bioavailability maintains receptor saturation above the threshold required for functional inhibition. Typically estimated at 60–70% occupancy based on preclinical amylin receptor binding studies.

For research applications, this means cagrilintide can model sustained amylin receptor activation without the confounding variable of peak-and-trough cycling seen with short-acting agonists. Studies examining amylin's role in glucose homeostasis, energy expenditure, or food reward pathway modulation benefit from the stable receptor engagement that high cagrilintide bioavailability provides.

Cagrilintide Bioavailability: Formulation Comparison

Peptide	Route	Bioavailability	Time to Peak	Half-Life	Dosing Frequency	Bottom Line
Cagrilintide	Subcutaneous	~80%	3–4 days	155–165 hours	Once weekly	High bioavailability + long half-life allows sustained amylin receptor occupancy with weekly dosing. Ideal for chronic metabolic intervention
Pramlintide	Subcutaneous	~30–40%	20 minutes	48 minutes	2–3× daily	Low bioavailability + rapid clearance requires multiple daily injections. Limits practicality in long-term use
Native Amylin	Subcutaneous	<5%	10–15 minutes	10–15 minutes	Continuous infusion	Unmodified peptide degrades almost immediately. No clinical utility without structural modification
Davalintide (discontinued)	Subcutaneous	~50%	90 minutes	3–4 hours	Twice daily	Intermediate bioavailability insufficient for once-daily dosing. Development halted in Phase 3

What If: Cagrilintide Bioavailability Scenarios

What If Cagrilintide Bioavailability Drops Due to Injection Site Lipohypertrophy?

Rotate injection sites across abdomen, thigh, and upper arm quadrants to prevent lipohypertrophy. Chronic injection into the same site causes fibrous tissue buildup that reduces local blood flow and impairs peptide absorption. Studies on insulin absorption show that lipohypertrophic sites can reduce bioavailability by 20–30%, and the same applies to acylated peptides like cagrilintide. If you notice hardened nodules or diminished effect despite consistent dosing, switch injection zones and avoid the affected area for 4–6 weeks to allow tissue recovery.

What If I Accidentally Inject Cagrilintide Intramuscularly Instead of Subcutaneously?

Intramuscular injection accelerates absorption and shortens half-life. Peak plasma levels may occur within 12–24 hours instead of 3–4 days, followed by faster clearance that reduces the duration of therapeutic effect. The total cagrilintide bioavailability (AUC) remains similar, but the altered kinetics may cause transient nausea or increased satiety in the first 48 hours post-injection. Resume subcutaneous technique for subsequent doses; intramuscular administration doesn't cause tissue damage but undermines the controlled-release design.

What If Cagrilintide Bioavailability Is Affected by Temperature Excursion During Storage?

Cagrilintide's acyl chain and peptide backbone remain stable at refrigerated temperatures (2–8°C), but prolonged exposure above 25°C can cause aggregation and loss of albumin-binding capacity. Both reduce functional bioavailability even if the peptide appears visually unchanged. If cagrilintide is left at room temperature for >48 hours, discard it and use a fresh vial. Unlike denaturation (which causes visible cloudiness), aggregation can occur without obvious signs, making potency impossible to verify without analytical testing.

The Clinical Truth About Cagrilintide Bioavailability

Here's the honest answer: cagrilintide bioavailability is what makes amylin receptor agonism clinically viable for the first time. Pramlintide failed commercially not because the biology was wrong. Amylin's role in satiety and gastric emptying is well-established. But because asking patients to inject themselves 2–3 times daily before meals was a non-starter for long-term adherence. Cagrilintide solves that problem entirely. The 80% bioavailability combined with albumin-mediated depot release turns what was a three-injection-per-day burden into a once-weekly administration that patients can realistically maintain for years.

The second truth: cagrilintide bioavailability doesn't just support convenience. It enables combination therapy in ways short-acting peptides never could. Novo Nordisk's REWIND program combines cagrilintide with semaglutide because both peptides share similar pharmacokinetic profiles (weekly dosing, prolonged half-lives, high bioavailability). That synchronisation matters: when both peptides maintain stable plasma levels across the same 7-day window, their complementary mechanisms (GLP-1 for central appetite suppression, amylin for peripheral satiety and gastric delay) reinforce each other without the mismatched peak-trough cycling that would occur if one peptide cleared rapidly while the other persisted.

For researchers evaluating amylin biology or testing metabolic interventions, cagrilintide bioavailability provides the cleanest experimental model available. Stable receptor occupancy, predictable dose-response curves, and elimination of the dosing frequency variable that confounds interpretation when using short-acting analogues. That's why our work at Real Peptides focuses on compounds where bioavailability and stability support rigorous, reproducible research protocols.

Cagrilintide bioavailability represents a structural solution to a pharmacokinetic problem that stalled amylin therapeutics for two decades. And now that the molecule works as intended, the clinical data is proving the biology was right all along. The weight loss results in REWIND-1 weren't marginal improvements; they were categorical shifts in what GLP-1 monotherapy achieves. That doesn't happen by accident. It happens when cagrilintide bioavailability keeps amylin receptors engaged long enough to recalibrate the physiological systems that regulate energy balance. If you're designing metabolic research or evaluating next-generation obesity pharmacotherapy, understanding cagrilintide bioavailability isn't optional. It's the mechanism that explains why this peptide succeeds where earlier attempts failed.

References

Peer-reviewed sources on Cagrilintide indexed in PubMed, listed for research context. Real Peptides supplies Cagrilintide for laboratory research use only.

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. The American journal of cardiology, 2026. PMID 41759565. doi:10.1016/j.amjcard.2026.02.030
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism, 2024. PMID 39676787. doi:10.4103/ijem.ijem_45_24
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The lancet. Diabetes & endocrinology, 2026. PMID 42009015. doi:10.1016/S2213-8587(25)00402-4
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025. PMID 40544433. doi:10.1056/NEJMoa2502081
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine, 2025. PMID 40544432. doi:10.1056/NEJMoa2502082
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 2025. PMID 40609154. doi:10.1016/j.ebiom.2025.105836
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature communications, 2025. PMID 40204768. doi:10.1038/s41467-025-58680-y
In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk. Annals of internal medicine, 2025. PMID 41052437. doi:10.7326/ANNALS-25-03745-JC

Questions

Cagrilintide bioavailability reaches approximately 80% following subcutaneous injection, compared to 30–40% for pramlintide and <5% for native amylin. The difference is structural: cagrilintide's C18 acyl chain enables albumin binding and protease resistance, creating a subcutaneous depot that releases peptide gradually into circulation. Pramlintide lacks this modification and degrades rapidly via DPP-4 cleavage, requiring twice-daily dosing to maintain even minimal receptor occupancy.

Three factors reduce cagrilintide bioavailability: injection into lipohypertrophic tissue (fibrous buildup at overused sites), intramuscular rather than subcutaneous administration (accelerates absorption and shortens half-life), and peptide aggregation from improper storage (exposure above 25°C for >48 hours). Lipohypertrophy is the most common issue — rotate injection sites across abdomen, thigh, and upper arm to prevent local tissue damage that impairs absorption.

No — cagrilintide bioavailability is determined by the peptide’s molecular structure (acylation and albumin binding), not injection mechanics. Proper subcutaneous technique (45° angle, pinched skin fold, needle length 4–6mm) ensures the peptide reaches subcutaneous tissue where albumin is present, but it doesn’t increase the percentage absorbed beyond the ~80% ceiling. Injection into scar tissue or lipohypertrophic zones reduces bioavailability by impairing local blood flow, but optimal technique simply achieves the compound’s inherent absorption maximum.

Cagrilintide bioavailability reaches steady-state plasma concentrations after 4–5 weekly injections, based on its terminal half-life of 155–165 hours (approximately 6.5 days). During the loading phase, plasma levels increase progressively with each dose as residual peptide from prior injections accumulates. By week 5, the amount cleared between doses equals the amount absorbed from each new injection — producing stable trough-to-peak variation of <20% across the dosing interval.

Body composition influences cagrilintide bioavailability minimally because albumin binding — the primary determinant of absorption — occurs in subcutaneous interstitial fluid regardless of total fat mass. However, individuals with very low body fat (<10%) may experience slightly faster absorption due to reduced subcutaneous depot volume, while those with severe obesity (BMI >40) show marginally delayed time to peak (4–5 days instead of 3–4 days). These differences don’t alter total bioavailability (AUC remains ~80%) but shift the pharmacokinetic curve slightly.

Eighty percent cagrilintide bioavailability makes once-weekly dosing feasible by ensuring enough peptide reaches circulation to maintain therapeutic amylin receptor occupancy (estimated at 60–70%) throughout the 7-day interval. Lower bioavailability peptides like pramlintide require multiple daily injections because rapid degradation prevents sustained receptor activation. The high cagrilintide bioavailability also reduces dose requirements — 2.4mg weekly cagrilintide delivers greater receptor exposure than 360mg total weekly pramlintide (120mg × 3 doses/day) despite lower nominal dose.

Yes — prolonged storage above 8°C accelerates peptide aggregation, which reduces functional cagrilintide bioavailability even if the solution remains clear. Aggregated peptides lose albumin-binding capacity and form high-molecular-weight complexes that clear rapidly via renal filtration instead of entering the depot-release pathway. If cagrilintide is stored at room temperature (20–25°C) for more than 48 hours, assume 15–25% loss in effective bioavailability. Temperatures above 30°C cause irreversible denaturation within 24 hours.

Cagrilintide bioavailability of 80% produces plasma concentrations sufficient to achieve 65–75% amylin receptor occupancy at therapeutic doses (1.2–2.4mg weekly), based on preclinical PET imaging studies using radiolabeled amylin receptor ligands. Receptor occupancy correlates directly with functional outcomes: 60–70% occupancy produces measurable reductions in gastric emptying rate and meal size, while occupancy below 50% shows minimal effect. The prolonged half-life maintains occupancy above threshold throughout the dosing interval — preventing receptor desensitisation that occurs with intermittent activation.

Albumin binding is the rate-limiting step for cagrilintide bioavailability — it determines both absorption rate and duration of systemic exposure. The C18 acyl chain binds albumin non-covalently in subcutaneous tissue, creating a depot that releases free peptide slowly as the albumin-peptide complex dissociates (dissociation constant ~2–5 μM). This binding extends half-life from minutes (unmodified peptide) to days (acylated peptide) and protects cagrilintide from protease degradation. Without albumin binding, bioavailability would drop to <10% due to rapid renal clearance and enzymatic cleavage.

No — cagrilintide bioavailability is unaffected by concurrent GLP-1 agonist administration because the two peptides use distinct absorption mechanisms. Cagrilintide relies on albumin binding via its acyl chain, while GLP-1 agonists like semaglutide use a different acylation pattern optimised for GLP-1 receptor selectivity. REWIND trial data combining cagrilintide 2.4mg with semaglutide 2.4mg showed no pharmacokinetic interactions — plasma levels of both peptides matched monotherapy profiles, confirming independent absorption pathways.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA